Biotech's biggest spenders; 10 largest U.S. patent losses; Mobile apps for drug developers;

> If you add up the R&D budgets for the top 15 public biotechs in the world, you'll find a tab that runs right about $10 billion. That's not small change, by any means, but to put it in some perspective, it is interesting to note that Roche, which has the largest research budget for any biopharma on the planet, spent a bit more than that last year advancing new drugs and technology. Biotech's biggest spenders

> Every year we look at the biggest CEO paychecks in the pharma industry. Despite a year fraught with manufacturing issues and drug recalls, Johnson & Johnson CEO Bill Weldon takes the top spot, with $28.7 million in 2010 pay. And Novartis' Daniel Vasella grabs the No. 2 spot thanks to a lucrative golden handshake. Top 10 pharma CEO salaries of 2010

> Let's face it, drug developers could use the efficiency that mobile apps promise. With big market opportunities across the life sciences industry, many companies have either developed smartphone- or tablet-compatible software versions or have launched and promoted their own dedicated mobile applications. Here we feature 10 apps that have been released or updated within the past two years. Slideshow

> In the drug business, exclusivity is everything. Once a branded drug gets generic competition, pricing power fades and sales slowly drain away, leaving drugmakers dependent on the next new thing. It's all very reasonable in theory, but when the drugs losing patent protection are the biggest in the business--and they're all falling off patent around the same time--even the most rational companies can get a bit panicky. 10 largest U.S. patent losses

> Halfway through 2011 we cataloged the five biggest VC deals. Biotech investing got off to a mediocre start during the first quarter but picked up steam in the second quarter. Dollars invested in biotech jumped 46% from the prior quarter, while the number of deals also rose 20% to 116 from 97 in the first quarter of 2011. Top 5 venture capital deals, H1 2011

> FierceBiotech IT looked at emerging IT companies whose businesses could take off and grow exponentially in the coming years. Though challenges remain, all of the companies are tackling different business challenges that life sciences companies face--including a need to draw meaning from huge amounts of phenotypic and genotypic data to advance drug R&D, how to gain visibility into the minute details of ongoing clinical trials to catch mistakes or make studies run efficiently, and giving scientists the IT tools that enable them to visualize chemical data and manage experiments. 5 emerging biotech IT firms to watch

> "G" is for green and for GSK. The U.K.-based Big Pharma is a leader among drugmakers bringing sustainability and green practices to facilities, manufacturing and supply chain operations. Economic drivers--including reductions in cycle times, energy use and costs--are prevailing over corporate responsibility as a reason to jump in feet first. The 12 greenest companies in biopharma

> Doctors, pharmacists and even the U.S. Congress use terms like "unprecedented," "crisis" and "significant risk" to describe current U.S. drug shortages. "We're getting to a tipping point, where we won't have medicines on the shelves," says Erin Fox, manager of the University of Utah Hospitals' Drug Information Service (DIS), a tracker of drug shortages, in an interview with FiercePharmaManufacturing. Here's our list of the top shortages as of early August. Top drug shortages by treatment category

> The trend in pharma GMP warning letters for 2011 is that there are more of them, with a higher proportion of warnings to foreign plants, as the letters in this report illustrate. Fierce's 2011 warning letters report

> 5 interesting medtech logos. Slideshow

And Finally... 10 unusual and puzzling biopharma company logos. Slideshow

Suggested Articles

The inclusion of Kupffer cells in in vitro hepatic cultures provides researchers with advanced tools for disease modeling and drug discovery.

A delay to Moderna's phase 3 COVID-19 study is part of a trend of tensions in the biotech’s relationship with the U.S. government, Reuters reported.

GlaxoSmithKline is continuing its strategy of giving out access to its vaccine platform as it adds Medicago to its growing partners list.